Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
16
×
clinical trials
16
×
life sciences
national blog main
novartis
16
×
national top stories
san francisco top stories
san francisco blog main
boston blog main
national
boston top stories
fda
new york top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
gene therapy
abbvie
amgen
cancer
roche
zolgensma
biogen
deals
immunotherapy
pfizer
What
roundup
bio
drug
new
fda
drugs
ipo
medicines
news
patients
approval
available
biofourmis
biological
biologics
biotech
blood
brings
cancer
can’t
cells
clears
company
convenience
days
deal
devices
digestive
enzymes
head
help
humans
hurdle
intended
nash
pill
proteins
public
rani’s
robotic
Language
unset
Current search:
biotech
×
novartis
×
" clinical trials "
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines